The world's top 10 pharmaceutical giants in 2007 third quarter results summary.

the world's top 10 pharmaceutical giants have announced the third quarter 2007 results, overall, the quarter's sales revenue of the companies in good shape. With the exception of Pfizer and GlaxoSmithKline, the pharmaceutical giants saw varying degrees of sales growth, with four companies growing by more than 10 per cent. The top three companies with the biggest sales growth in the top 10 were Abbott, Johnson and Johnson and Merck, with growth of 14 per cent, 12.7 per cent and 12 per cent respectively. Among the two companies with lower sales, GlaxoSmithKline fell 3 percent, followed by Pfizer, which fell 2 percent.. The pharmaceutical giants' net earnings were relatively poor in the quarter. With the exception of Roche, which reported unannounced net earnings, five pharmaceutical giants reported varying degrees of decline in net income, one flat and three growths. Among the top 10, the biggest increase in net income in the quarter was Novartis, which rose by 266.8 per cent, but not as an operating income but a one-off income from the company's divestiture of its two divisions. This was followed by Merck and Sanofi-aventis, with net income growth of 62 per cent and 9 per cent, respectively. The three companies with the biggest declines in net income were Pfizer, AstraZeneca and Johnson and Johnson, down 77 per cent, 15 per cent and 7.7 per cent, respectively.. In the third quarter of 2007, the pharmaceutical giant's sales revenue and net income profilecompany name sales revenue (US$100 million) growth (%) net income (US$100 million) (%)Pfizer 120-27.61-77Johnson and Johnson 150-12.725-7.7Sanofi-Avant 7 EUR 0 billion plus 41.9 billion euros and 9Novartis 96.6 6,266.8GlaxoSmithKline 5.5 billion - 31.3 billion pounds - 6Roche 11.1 billion Swiss franc s.6///Merck 61-1215-62
.
. AstraZeneca's 71.5-1013.4-15Wyeth 56-911.5-1Abbott 64-147.17-0.1 1, Pfizer Inc., Inc., Inc., Inc., Inc., Inc., Inc., Inc., Inc., Inc., Inc., inc. reported a 77 percent drop in third-quarter net income, ending sales of ExuberaPfizer, and its third-quarter 2007 results. Net revenue fell 77 percent to $761 million in the quarter, hurt by the end of sales of the inhaled diabetes drug Exubera, competition from generic drugs, and sales of the lipid-lowering drug atorvastatin, lipto, Lipitor.. Pfizer said it made a decision after careful consideration to end the sale of the insulin-dry powder inhaler Exubera, which involved a $2.8 billion related expense. The product was once considered a bomb-heavy drug of the future, and the company has high hopes for it. However, despite Pfizer's efforts, Exubera was not accepted by patients and doctors. Pfizer has decided to discontinue the sale of this product in view of the risk of further investment. Pfizer said it plans to return Exubera's license to partner Nektar Therapeutics and shift patients to other diabetes treatments in the coming months. Pfizer stopped production at its Indiana plant and paid for the release of its employees.. Sales of prescription drugs fell 4 percent to $11 billion in the quarter. The anti-arthritis drug Celecoxib, Celebrex, rose 8 percent to $577 million in the quarter. Sales of pribalin, the neuropathic pain and epilepsy treatment drug, rose 37 percent to $465 million. Sales of the erectile dysfunction treatment drug Sidnafil (Van Aico, Viagra) rose 6 percent to $450 million. Sales of the smoking cessation drug vareniclinetrate (Chantix) were $241 million, up from $33 million a year earlier.. Lipitor's sales fell 5 percent to $3.2 billion in the quarter. Pfizer expects Lipitor sales to fall 3 to 5 percent for the full year. Anti-
hypertension
drugs amlodipine, norvasc, Norvasc, and the antidepressant sertraline, Zolofu, Zoloft, both fell in sales as a result of competition from generic drugs in the United States. Norvasc's sales fell 47 percent to $640 million in the quarter. Zoloft's sales fell 73 percent to $124 million. Overall, Pfizer's sales fell 2 percent to $12 billion in the quarter, beating analysts' expectations of $11.8 billion. . 2, Johnson and Johnson: Third quarter prescription drug sales growth, net income fell 7.7% Johnson and Johnson reported third-quarter 2007 results, prescription drug sales rose 3.7 percent to $6.1 billion. Sales of antipsychotic drugs, including the drug risperidone, rose 8.9 percent to $1.2 billion. . Revenue from antiarthritis drugs and sectional enteritis drugs infliximab, Remicade, rose 5.5 percent to $819 million in the quarter. However, sales of the anti-anemia drug erythropoietin fell 14.6 percent to $682 million, limited by increased red blood cell-generating factor warning labels and changes in Medicare benefits in the U.S. Topiramate, topamax, the treatment for epilepsy and migraines, rose 15 percent to $613 million in the quarter. Sales of the anti-infective drug levofloxacin rose 4.6 percent to $366 million. Sales of the attention deficit and hyperactivity disorder treatment drug methylphenidate HCI, Concerta, increased 5.3 percent to $231 million. . Overall, net income fell 7.7 percent to $2.5 billion in the quarter. This was mainly due to $528 million in cost-saving spending in July. Revenue rose 12.7 percent to $15 billion in the quarter, beating analysts' expectations of $14.8 billion. . There is a view that even though the Risperdal and Topamax patents are about to expire, The company's earnings per share growth will still be around 10 per cent over the next three years. It is also understood that Johnson and Johnson raised its 2007 earnings forecast, expected earnings per share of $4.10 to $4.13, the previous estimate of 4.02 to 4.07 U.S. dollars. . 3. Sanofi-Aventis: Net income rose 9% in the third quarter French pharmaceutical company Sanofi-aventis reported third-quarter 2007 results. . Sanofi-Avant's net income rose 9 per cent to 1.9bn euros ($2.7bn), beating industry analysts' expectations of 1.7bn euros, helped by sales growth in the anticoagulant clopidogrel, Plavix, and strong sales of vaccine products. The company raised its full-year earnings growth forecast, which is expected to grow by 10 per cent, compared with a previous forecast of 9 per cent. . Sales of enoxaparin, the blood disease treatment drug, rose 13 percent to 633 million euros in the quarter. Plavix's sales revenue rose 13 percent to 614 million euros. Sales of the anti-
-
drug docetaxel, Tessotti, Taxotere rose 14 percent to 475 million euros. Sales of the diabetes treatment drug insulinglargine (Glargargine, Lantus) rose 31% to 518 million euros. Sales of vaccine products increased by 49% to 943 million euros. . Prescription drug sales fell slightly to 6.1 billion euros in the quarter. This is mainly due to competition from generic drugs in the U.S. market for the sleep disorder treatment drug zolpidemtatatatatate, and competition from the European market for the colorectal cancer treatment drug oxaliplatin, Eloxatin. AmbienIR's sales fell to 35 million euros, compared with 352 million euros a year earlier. Eloxatin's sales fell 5 percent to 383 million euros. Overall, sales rose 4 percent to 7 billion euros in the quarter, beating analysts' expectations of 6.7 billion euros to 6.9 billion euros. . Sales of the smoking cessation and obesity treatment drug, Lionabant, acoa, were flat in the quarter, at 21 million euros. It is understood that the FDA took into account the safety of this product to reject Acomplia's listing application, Sanofi-Avant withdrew the product for the treatment of obesity in the United States listing application. The company said it plans to expand its research and development for the treatment of type 2 diabetes. Sanofi-Avant plans to submit a listing application for the treatment of type 2 diabetes in 2009. . Sanofi-Avant is understood to have cut nearly 3,000 jobs in the US and Europe since 2005 and the company said it would continue to cut administrative and sales costs. . Novartis, Novartis, the second-largest pharmaceutical company in Europe, announced plans to cut 1,260 jobs in the U.S. while changing its prescription drug division, with a 9 percent job growth in the third quarter and a 1,000-point job cut. It is understood that Joe Jimenez will replace Thomas Ebeling in charge of the company's prescription drug division, while Thomas Ebeling has been appointed head of the company's consumer
health care
. . Novartis' net income rose to $6.86 billion, or $2.97 per share, in the quarter, compared with $1.87 billion, or $0.80 per share, a year earlier, on the back of a one-time revenue of $5.2 billion from the divestiture of the healthcare and
infant
food division. Excluding one-time income, net income fell 12 percent to $1.57 billion. Revenue rose 9 percent to $9.6 billion in the quarter. . Revenue from prescription drug sales rose 2 percent to $5.9 billion in the quarter. Anti-
hypertension
valsartan, Diovan, rose 16 percent to $1.3 billion. Sales of the leukemia treatment drug imatinib, Grewe, Glivec/Gleevec rose 20 percent to $783 million. Including anti-
hypertension
drug Aliskiren (Tekturna/Rasilez), anti-
hypertension
drug satan and atomchloric pine compound formulation (valsartan-amlodipine, Exforge), iron overload drug overload drugs New products including Exirox, the wet age-related macular degeneration drug ranibizumab (Lucentis) and the anti-asthma drug omalizumab (Xolair) combined for revenue of about $300 million in the quarter. . It is understood that anti-
hypertension
drug Tekturna earlier this year through the FDA approval, this product will compete with Exforge market. Analysts expect Tekturna's sales to reach $300 million in 2008 and Exforge to about $500 million. . However, Novartis' third-quarter results were also adversely affected by competition for generic drugs and
recalls of
drugs. The antifungal drug terbinafine, Lamisil and anti-
hypertension
the drug benzool acid achlorodipin a hydrochloric acid benapricompound compound preparation (amlodipine).